Healthcare | August 13, 2021
HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Substantial reduction in losses
Substantial reduction in losses
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The aim is to create new genomics solutions that could combat cancer and advance market access
If approved it will bring a second source of MMR vaccine to the US market
The American Association for Clinical Chemistry (AACC); the American Society for Clinical Pathology (ASCP); the American Society of Hematology (ASH); and the International Myeloma Working Group (IMWG), collaborate to develop the guideline
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
Subscribe To Our Newsletter & Stay Updated
